AstraZeneca Respiratory Head: Tezepelumab Could Be 'Game Changer'

AstraZeneca's first in class biologic tezepelumab, which targets TSLP, has revolutionary potential in treating severe asthma, the UK drug maker's respiratory head tells Scrip.